跳至主導覽
跳至搜尋
跳過主要內容
排序方式
Keyphrases
Area under the Curve
11%
Chest Computed Tomography Image
11%
Clinical Data
11%
Clinical Features
22%
Clinical Model
11%
Computed Tomography
11%
Deep Learning Methods
100%
Disease Progression
11%
Early Prediction
11%
EGFR mutation
11%
Epidermal Growth Factor Receptor
33%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
66%
First-line Therapy
11%
Individualized Prediction
11%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
11%
Model Combining
11%
Multi-time
11%
Non-small Cell Lung Cancer (NSCLC)
100%
Non-small Cell Lung Cancer Patients
11%
Patient Management
22%
Performance Prediction
11%
Personalized Management
11%
Prediction Accuracy
11%
Progression-free Survival
100%
Quantitative Computed Tomography
11%
Radiomics
100%
Risk of Progression
11%
Risk Stratification
11%
Survival Curve
33%
Survival Prediction
22%
Treatment Strategy
11%
Tumor Control
11%
Tumor Progression
22%
Tyrosine Kinase Inhibitor
11%
Tyrosine Kinase Inhibitor Therapy
100%
Tyrosine Kinase Inhibitor Treatment
33%
Biochemistry, Genetics and Molecular Biology
Computer Assisted Tomography
30%
Epidermal Growth Factor Receptor
100%
Progression Free Survival
100%
Radiomics
100%
Receptor Tyrosine Kinase Inhibitors
60%
Survival Prediction
20%
Tumor Progression
20%
Tyrosine Kinase Inhibitor
100%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Feature
11%
Disease Exacerbation
11%
Epidermal Growth Factor Receptor
44%
Epidermal Growth Factor Receptor Kinase Inhibitor
66%
Neoplasm
11%
Non Small Cell Lung Cancer
100%
Progression Free Survival
100%
Protein Tyrosine Kinase Inhibitor
100%
Survival Prediction
22%
Tumor Growth
22%
Neuroscience
Computed Tomography
30%
Epidermal Growth Factor Receptor
100%
Receptor Tyrosine Kinase Inhibitors
60%
Tyrosine Kinase Inhibitor
100%